# Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection

> **NCT04165122** · PHASE2 · COMPLETED · sponsor: **Heidelberg ImmunoTherapeutics GmbH** · enrollment: 122 (actual)

## Conditions studied

- Herpes Genitalis

## Interventions

- **BIOLOGICAL:** HDIT101
- **DRUG:** Valaciclovir
- **BIOLOGICAL:** HDIT101 placebo
- **DRUG:** Valaciclovir placebo

## Key facts

- **NCT ID:** NCT04165122
- **Lead sponsor:** Heidelberg ImmunoTherapeutics GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-15
- **Primary completion:** 2021-08-25
- **Final completion:** 2021-11-01
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2022-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04165122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04165122, "Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04165122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*